|
Market Closed -
Nasdaq
00:00:00 29/08/2026 +04
|
5-day change | 1st Jan Change | ||
| 218.50 USD | -1.35% |
|
+0.79% | +24.15% |
| 08-25 | Veeva Systems Secures Biogen, Regeneron Pharmaceuticals as New Vault CRM Clients | MT |
| 08-25 | RBC Capital Adjusts Price Target on Biogen to $260 From $240, Keeps Outperform Rating | MT |
Company Valuation: Biogen Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 35,242 | 39,877 | 37,495 | 22,283 | 25,818 | 32,284 | - | - |
| Change | - | 13.15% | -5.97% | -40.57% | 15.86% | 25.04% | - | - |
| Enterprise Value (EV) 1 | 37,820 | 40,560 | 43,384 | 26,204 | 28,289 | 37,221 | 34,704 | 31,632 |
| Change | - | 7.24% | 6.96% | -39.6% | 7.96% | 31.57% | -6.76% | -8.85% |
| P/E | 23.1x | 13.3x | 32.5x | 13.7x | 20x | 38.8x | 19.1x | 15.4x |
| PBR | 3.26x | 3.02x | 2.53x | 1.33x | 1.42x | 1.75x | 1.58x | 1.44x |
| PEG | - | 0x | -0.5x | 0.3x | -0.9x | -1.1x | 0x | 0.6x |
| Capitalization / Revenue | 3.21x | 3.92x | 3.81x | 2.3x | 2.61x | 3.09x | 3.03x | 2.95x |
| EV / Revenue | 3.44x | 3.99x | 4.41x | 2.71x | 2.86x | 3.56x | 3.26x | 2.89x |
| EV / EBITDA | 9.13x | 11.2x | 14.3x | 7.1x | 7.82x | 13.6x | 10.1x | 8.65x |
| EV / EBIT | 10.3x | 13.1x | 17x | 8.69x | 9.97x | 14.8x | 10.8x | 9.01x |
| EV / FCF | 11.2x | 35.5x | 34.2x | 9.63x | 13.8x | 20x | 14.6x | 11.6x |
| FCF Yield | 8.94% | 2.82% | 2.93% | 10.4% | 7.25% | 4.99% | 6.84% | 8.59% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 10.4 | 20.87 | 7.97 | 11.18 | 8.79 | 5.628 | 11.41 | 14.22 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 10,982 | 10,173 | 9,836 | 9,676 | 9,891 | 10,442 | 10,659 | 10,959 |
| EBITDA 1 | 4,144 | 3,618 | 3,040 | 3,689 | 3,618 | 2,740 | 3,453 | 3,656 |
| EBIT 1 | 3,656 | 3,099 | 2,545 | 3,015 | 2,838 | 2,514 | 3,203 | 3,511 |
| Net income 1 | 1,556 | 3,047 | 1,161 | 1,632 | 1,293 | 953.1 | 1,899 | 2,247 |
| Net Debt 1 | 2,578 | 683 | 5,888 | 3,921 | 2,471 | 4,937 | 2,420 | -652.2 |
| Reference price 2 | 239.92 | 276.92 | 258.77 | 152.92 | 175.99 | 218.50 | 218.50 | 218.50 |
| Nbr of stocks (in thousands) | 146,893 | 144,001 | 144,898 | 145,719 | 146,702 | 147,754 | - | - |
| Announcement Date | 03/02/22 | 15/02/23 | 13/02/24 | 12/02/25 | 06/02/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 38.82x | 3.56x | 13.58x | -.--% | 32.28B | |
| 18.39x | 4.28x | 10.08x | 0.49% | 79.3B | |
| 20.35x | 4.33x | 13.36x | 2.44% | 59.21B | |
| -16.37x | 24.54x | -15.89x | -.--% | 55.09B | |
| 36.19x | 12.33x | 23.67x | -.--% | 49.86B | |
| 21.68x | 4.79x | 13.66x | 0.67% | 47.9B | |
| 55.5x | 3.53x | 27.36x | -.--% | 25.21B | |
| 71.76x | 7.68x | 46.71x | -.--% | 23.87B | |
| 24.44x | 5.24x | 13.65x | -.--% | 16.89B | |
| 75.15x | 45.28x | 65.75x | 0.15% | 16.17B | |
| Average | 34.59x | 11.56x | 21.19x | 0.37% | 40.58B | |
| Weighted average by Cap. | 26.12x | 9.86x | 15.00x | 0.54% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- BIIB Stock
- Valuation Biogen Inc.
Select your edition
All financial news and data tailored to specific country editions
